An investigative report published in 2023 examined the STAR*D antidepressant trial, a federally funded study that shaped depression treatment guidelines for years.

STAR*D originally claimed that nearly 70% of patients eventually became symptom-free after multiple medication attempts.

The later analysis, however, argued that the reported numbers were inflated through protocol violations, selective reporting, and altered outcome measurements.